Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOESTRIN FE 1.5/30 vs DHIVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Treatment of dysmenorrhea (off-label),Treatment of acne (off-label)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.
DHIVY is not a recognized drug. No dosing information available.
Norethindrone: ~5-14 hours (terminal); Ethinyl estradiol: ~13-27 hours (terminal). Clinically, steady-state achieved within 5-7 days.
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Metabolized in liver via CYP3A4 (norethindrone) and hydroxylation/conjugation (ethinyl estradiol).
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Renal: ~50-60% (norethindrone metabolites); Fecal: ~20-30% (norethindrone); Ethinyl estradiol: primarily renal (~40-50%) and fecal (~20-50%) as glucuronide and sulfate conjugates.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Norethindrone: ~80-90% bound to SHBG and albumin; Ethinyl estradiol: ~95-98% bound primarily to albumin (with some to SHBG).
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Norethindrone: ~4 L/kg; Ethinyl estradiol: ~4-10 L/kg; indicates extensive tissue distribution.
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: Norethindrone ~64%; Ethinyl estradiol ~38-48% (due to first-pass metabolism).
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
No dose adjustment required for renal impairment; however, use with caution in patients with impaired renal function due to potential fluid retention.
Not applicable.
Contraindicated in acute hepatic disease or liver tumors (benign or malignant). For Child-Pugh Class A, no dose adjustment; avoid use in Class B or C.
Not applicable.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily.
Not applicable.
Not indicated for use in postmenopausal women. No specific geriatric dosing.
Not applicable.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day) and is significant in women over 35. Women who use combination oral contraceptives should be strongly advised not to smoke.
No FDA black box warnings.
Increased risk of thromboembolic events; cardiovascular disease; hypertension; gallbladder disease; hepatic neoplasia; elevated liver enzymes; possible increased risk of breast/cervical cancer; glucose intolerance; fluid retention; hereditary angioedema; chloasma; irregular bleeding; depression; contact lens intolerance; possible reduced efficacy with enzyme-inducing drugs.
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; carcinoma of endometrium or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; current or history of migraine with aura (age ≥35); heavy smoking (≥15 cigarettes/day) in women ≥35 years; uncontrolled hypertension; diabetes with vascular involvement; major surgery with prolonged immobilization; known thrombophilic conditions.
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
No significant food interactions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically relevant. Separate iron tablets from high-calcium foods or supplements (e.g., dairy) to enhance iron absorption, but this does not affect contraceptive efficacy.
No data available for DHIVY.
FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second and third trimesters: associated with fetal harm, including masculinization of female fetuses due to progestin component. No safe use during pregnancy.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Small amounts of ethinyl estradiol and norethindrone acetate excreted in breast milk; M/P ratio not reported. May reduce milk production and quality. Use only if clearly needed; lowest effective dose recommended. Caution in nursing mothers.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Contraindicated in pregnancy; no dosing adjustment applicable. Discontinue immediately if pregnancy occurs.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
Loestrin Fe 1.5/30 contains norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg plus ferrous fumarate (75 mg) as placebo pills. The iron supplement does not affect contraceptive efficacy. Be aware of increased risk of venous thromboembolism, especially in smokers over 35. Use with caution in patients with migraine with aura. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy. Breakthrough bleeding is common in first few cycles. Do not use in patients with hepatic impairment or known thrombophilia.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
Take one tablet daily at the same time each day, starting on the first day of menstrual bleeding.,The first 21 tablets are active hormones; the last 7 tablets are iron supplements that do not prevent pregnancy.,Missed dose: if you miss one active tablet, take it as soon as remembered; no backup needed. If you miss two, take two tablets and use backup contraception for 7 days.,Iron tablets may cause dark stools; this is harmless.,Report symptoms of blood clots: sudden leg pain, chest pain, shortness of breath, or severe headache.,Use additional contraception if starting within 5 days of stopping another hormonal contraceptive.,Avoid smoking while on this medication, especially if over 35.
Do not use this drug without correct identification.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOESTRIN FE 1.5/30 vs DHIVY, answered by our medical review team.
LOESTRIN FE 1.5/30 is a Combined Oral Contraceptive that works by Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.. DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOESTRIN FE 1.5/30 and DHIVY depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOESTRIN FE 1.5/30 is: One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.. The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOESTRIN FE 1.5/30 and DHIVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOESTRIN FE 1.5/30 is classified as Category C. FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second and. DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.